Premium
PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY
Author(s) -
Zinzani P.L.,
Fanale M.A.,
Chen R.,
Armand P.,
Johnson N.,
Brice P.,
Radford J.,
Ribrag V.,
Molin D.,
Vassilakopoulos T.P.,
Tomita A.,
Tresckow B.,
Shipp M.A.,
Zhang Y.,
Balakumaran A.,
Moskowitz C.H.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_125
Subject(s) - medicine , pembrolizumab , refractory (planetary science) , oncology , brentuximab vedotin , phases of clinical research , lymphoma , chemotherapy , cancer , hodgkin lymphoma , immunotherapy , physics , astrobiology